CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation

CONCERT-1 (1) is an international, open-label, randomized, controlled, phase 2 trial, in which 150 patients with previously untreated stage III, IVa, or IVb, locally advanced (LA) non-nasopharyngeal squamous cell carcinoma of the head and neck (HNSCC) from 41 sites in 9 countries were randomly assigned 2:3 to open-label concurrent chemoradiotherapy (CCRT) (three cycles of cisplatin 100 mg/m²) or panitumumab plus CCRT (three cycles of intravenous panitumumab 9.0 mg/kg every
3 weeks plus cisplatin 75 mg/m²).